King & Spalding has recruited highly-regarded Bay Area corporate transactional lawyer Thomas Duley as a partner in the firm’s Silicon Valley office to anchor its growing technology transactions practice dedicated to the life sciences industry. Duley joins King & Spalding from DLA Piper.

“Tom will play a key role in the growth of our corporate and life sciences teams in the Silicon Valley office,” said Timothy T. Scott, managing partner of King & Spalding’s Palo Alto office. “Working collaboratively with partners in the firm’s early-stage corporate, intellectual property and transactional practices, he will help us expand our life sciences transaction practice in the Bay Area and throughout the United States.”

Duley concentrates on complex technology agreements and commercial transactions for life sciences companies. He advises clients on strategic partnering and collaboration agreements, joint ventures, intellectual property licenses, sponsored research agreements, co-promotion, supply, distribution, clinical trial, material transfer and other commercial agreements, as well as litigation settlements and M&A and capital markets transactions. Duley received his law degree from the University of California, Davis School of Law and his masters and undergraduate degrees from the University of California, Los Angeles.

“Tom is an important addition to the talent base we offer to our life sciences clients, and we welcome him to the firm” said Andrew T. Bayman, a leader of King & Spalding’s life sciences practice. “His experience working with early stage and start-up life sciences companies will be of particular benefit to the firm’s clients, especially those on the West Coast.”

“I am thrilled to become part of the impressive corporate and life sciences teams at King & Spalding,” said Duley. “I have known and respected Laura Bushnell — who is leading the firm’s efforts to grow its life sciences corporate practice in California — for many years, and look forward to working with her and the firm’s other talented lawyers to build out a dedicated technology transactions practice for life sciences companies.”